Figure 3
Patient survival rate in months since hepatocellular carcinoma (HCC) diagnosis. (A) HCC Patients with positive history of hepatitis c (HCV) infection (n = 470) versus patients with no history of HCV (n = 363) (p = 0.22). (B) HCC and HCV patients that received a direct-acting antiviral (DAA) (n = 123) versus those who did not receive a DAA (n = 247) (p < 0.0001). (C) Patients with HCC and HCV that received a DAA and achieved sustained viral response (SVR12) (n = 83) versus those who did not achieve SVR12 (n = 31) (p < 0.0001).
